Jonathan E Brammer1, Dai Chihara2, L Michelle Poon3, Paolo Caimi4, Marcos de Lima4, Celina Ledesma5, Gabriela Rondon5, Stefan O Ciurea5, Yago Nieto5, Michelle Fanale2, Bouthaina Dabaja6, Richard T Maziarz7, Richard E Champlin5, Chitra Hosing5, Yasuhiro Oki2. 1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: jbrammer1982@gmail.com. 2. Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 3. National University Health System Singapore, Singapore. 4. University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA. 5. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 6. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 7. Oregon Health and Science University, Knight Cancer Institute, Center for Hematologic Malignancies, Portland, OR.
Abstract
BACKGROUND: Extra-Nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year. Patients with advanced stage III/IV ENKL and relapsed refractory ENKL have a poor prognosis even despite aggressive therapy and stem cell transplantation (SCT). We conducted a review of the management of 37 patients with advanced-stage and relapsed/refractory ENKL in a predominantly non-Asian cohort evaluating both chemotherapy and SCT outcomes. PATIENTS AND METHODS: We evaluated clinical outcomes in all patients treated for advanced stage III/IV or relapsed/refractory ENKL at MD Anderson cancer center between 2000-2014. Next, we collected stem cell transplant data from four transplant institutions to further evaluate outcomes of both allogeneic (allo-SCT) and autologous (auto-SCT) stem cell transplantation in ENKL. RESULTS: OS and PFS were 73% and 45% at one year, and 30% and 19% at 3-years, respectively. SMILE chemotherapy was more effective in maintaining a CR compared to CHOP (83% vs 17%). Only achievement of CR was prognostic for OS (HR 0.245, p=0.002) and PFS (HR 0.072, p) CONCLUSION: Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients.
BACKGROUND: Extra-Nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year. Patients with advanced stage III/IV ENKL and relapsed refractory ENKL have a poor prognosis even despite aggressive therapy and stem cell transplantation (SCT). We conducted a review of the management of 37 patients with advanced-stage and relapsed/refractory ENKL in a predominantly non-Asian cohort evaluating both chemotherapy and SCT outcomes. PATIENTS AND METHODS: We evaluated clinical outcomes in all patients treated for advanced stage III/IV or relapsed/refractory ENKL at MD Anderson cancer center between 2000-2014. Next, we collected stem cell transplant data from four transplant institutions to further evaluate outcomes of both allogeneic (allo-SCT) and autologous (auto-SCT) stem cell transplantation in ENKL. RESULTS: OS and PFS were 73% and 45% at one year, and 30% and 19% at 3-years, respectively. SMILE chemotherapy was more effective in maintaining a CR compared to CHOP (83% vs 17%). Only achievement of CR was prognostic for OS (HR 0.245, p=0.002) and PFS (HR 0.072, p) CONCLUSION: Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients.
Authors: E Tse; T S Y Chan; L-P Koh; W-J Chng; W-S Kim; T Tang; S-T Lim; A K W Lie; Y-L Kwong Journal: Bone Marrow Transplant Date: 2014-04-28 Impact factor: 5.483
Authors: Bethany L Mundy-Bosse; Christoph Weigel; Yue-Zhong Wu; Salma Abdelbaky; Youssef Youssef; Susana Beceiro Casas; Nicholas Polley; Gabrielle Ernst; Karen A Young; Kathleen K McConnell; Ansel P Nalin; Kevin G Wu; Megan Broughton; Matthew R Lordo; Ekaterina Altynova; Everardo Hegewisch-Solloa; Daniel Y Enriquez-Vera; Daniela Dueñas; Carlos Barrionuevo; Shan-Chi Yu; Atif Saleem; Carlos J Suarez; Edward L Briercheck; Hernan Molina-Kirsch; Thomas P Loughran; Dieter Weichenhan; Christoph Plass; John C Reneau; Emily M Mace; Fabiola Valvert Gamboa; David M Weinstock; Yasodha Natkunam; Michael A Caligiuri; Anjali Mishra; Pierluigi Porcu; Robert A Baiocchi; Jonathan E Brammer; Aharon G Freud; Christopher C Oakes Journal: Blood Cancer Discov Date: 2022-03-01
Authors: John C Reneau; Polina Shindiapina; Zachary Braunstein; Youssef Youssef; Miguel Ruiz; Saira Farid; Walter Hanel; Jonathan E Brammer Journal: J Clin Med Date: 2022-05-10 Impact factor: 4.964
Authors: Won Seog Kim; Yasuhiro Oki; Seok Jin Kim; Sang Eun Yoon; Kirit M Ardeshna; Yi Lin; Jia Ruan; Pierluigi Porcu; Jonathan E Brammer; Eric D Jacobsen; Dok Hyun Yoon; Cheolwon Suh; Felipe Suarez; John Radford; Lihua E Budde; Jin Seok Kim; Emmanuel Bachy; Hun Ju Lee; Catherine M Bollard; Arnaud Jaccard; Hye Jin Kang; Shannon Inman; Maryann Murray; Katherin E Combs; Daniel Y Lee; Ranjana Advani; Kurt C Gunter; Cliona M Rooney; Helen E Heslop Journal: Ann Hematol Date: 2021-07-24 Impact factor: 3.673